March 28, 2024 – Medtronic introduced that the U.S. Meals and Drug Administration (FDA) has authorized the Evolut™ FX+ Transcatheter Aortic Valve Alternative System (TAVR) for the therapy of symptomatic extreme aortic stenosis. The newest Evolut FX+ TAVR system retains the valve efficiency advantages of the older Evolut TAVR platform and is designed to facilitate coronary entry.

The Evolut FX+ TAVR System supplies bigger coronary entry home windows by means of a modified diamond body design, which is 4 occasions bigger than earlier variations of the Evolut TAVR System. Evolut FX+ supplies elevated catheter maneuverability to facilitate entry to coronary arteries with totally different affected person anatomies. Moreover, the brand new design doesn’t compromise the market-leading valve efficiency, glorious hemodynamics and radial pressure that physicians count on from the Evolut platform.

Study extra